Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis

New England Journal of Medicine

Volumn 353, Issue 21, 2005, Pages 2254-2261

  Groszmann, Roberto J ^a,b   Garcia Tsao, Guadalupe ^a,b   Bosch, Jaime ^c   Grace, Norman D ^d,e   Burroughs, Andrew K ^f   Planas, Ramon ^g   Escorsell, Angels ^c   Garcia Pagan, Juan Carlos ^c   Patch, David ^f   Matloff, Daniel S ^e   Gao, Hong ^b   Makuch, Robert ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Brigham and Women's/Faulkner Hospitals   (United States)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TIMOLOL;

ADULT; ARTICLE; ASCITES; BRADYCARDIA; BRAIN DISEASE; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEPRESSION; FATIGUE; FEMALE; HEART FAILURE; HUMAN; HYPOTENSION; IMPOTENCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TREATMENT OUTCOME; WHEEZING;

ADRENERGIC BETA-ANTAGONISTS; ADULT; DOUBLE-BLIND METHOD; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART RATE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIMOLOL; TREATMENT FAILURE;

EID: 28144455912     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa044456     Document Type: Article

References (35)

1. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985;5:97-101.
2. Kroeger RJ, Groszmann RJ. Idem. Effect of selective blockade of beta-2 adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model. Gastroenterology 1985;88:896-900.
3. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505. [Erratum, Semin Liver Dis 2000;20:399.]
4. Sarin SK, Groszmann RJ, Mosca PG, et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest 1991;87:1032-6.
5. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004;39:280-3.
6. Christensen E, Fauerholdt L, Schlichting P, Juhl E, Poulsen H, Tygstrup N. Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisolone. Gastroenterology 1981;81:944-52.
7. Cales P, Desmorat H, Vinel JP, et al. Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. Gut 1990;31:1298-302.
8. Cales P, Oberti F, Payen JL, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. Eur J Gastroenterol Hepatol 1999;11:741-5.
9. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476-84.
10. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Goodman Gilman A, Goodman LS, Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980:176-210.
11. Jennings G, Bobik A, Korner P. Comparison of effectiveness of timolol administered once a day and twice a day in the control of blood pressure in essential hypertension. Med J Aust 1979;2:263-5.
12. Wang T, Kaumann AJ, Brown MJ. (-)-Timolol is a more potent antagonist of the positive inotropic effects of (-)-adrenaline than of those of (-)-noradrenaline in human atrium. Br J Clin Pharmacol 1996;42:217-23.
13. Escorsell A, Ferayorni L, Bosch J, et al. The portal pressure response to β-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997;112:2012-6.
14. Garcia-Tsao G, Grace N, Groszmann RJ, et al. Short term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-6.
15. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A. Differences between acute and chronic effects of nadolol on portal hypertension in patients with cirrhosis: a pathophysiological interpretation. Hepatology 2004;40:Suppl 1:627A. abstract.
16. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-61. [Erratum, N Engl J Med 1988;318:994.]
17. Lebrec D, Poynard T, Capron JP, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis: a randomized trial. J Hepatol 1988;7:118-25.
18. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients: final report of a multicenter randomized trial. J Hepatol 1989;9:75-83.
19. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of the first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
20. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997;113:1632-9.
21. Borroni G, Salerno F, Cazzaniga M, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol 2002;37:315-21.
22. Merkel C, Marin R, Enzo E, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996;348:1677-81.
23. Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003;37:1260-6.
24. Abecasis R, Kravetz D, Fassio E, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003;37:359-65.
25. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. Hepatology 1991;14:1016-24.
26. Sheen IS, Chen TY, Liaw YF. Randomized controlled study of propranolol for the prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver 1989;9:1-5.
27. Westaby D, Polson RJ, Gimson AES, Hayes PC, Hayllar K, Williams R. A controlled trial of oral propranolol compared with injection sclerotherapy for the longterm management of variceal bleeding. Hepatology 1990;11:353-9.
28. Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-9.
29. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-55.
30. Ishizaki T, Tawara K. Comparison of disposition and effect of timolol and propranolol on exercise tachycardia. Eur J Clin Pharmacol 1978;14:7-14.
31. D'Amico G, Garcia-Tsao G, Cales P, et al. Diagnosis of portal hypertension: how and when. In: DeFranchis R, ed. Portal Hypertension III: Proceeding of the III Baveno International Consensus Workshop on Definition, Methodology, and Therapeutic Strategies. Oxford, U.K.: Blackwell Science, 2001:36-64.
32. Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
33. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902-8.
34. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701-9.
35. Aracil C, Lopez-Balaguer JM, Monfort D, et al. Hemodynamic response to betablockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis. Hepatology 2003;38:296A. abstract.